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Abstract Functionalized dialdehydes are considered important sub-
strates that can be transformed into various substituted heterocyclic,
alicyclic, and polysubstituted compounds. Here, we report a robust ste-
reocontrolled procedure for the synthesis of novel functionalized triflu-
oromethyl-containing piperidine and azepane derivatives, based on oxi-
dative ring cleavage of the C=C bond of diversely substituted
cycloalkenes, followed by reductive ring closure of the diformyl inter-
mediates in the presence of fluorine-containing amines.
Key Words aldehydes, alkylation, amino acids, bioorganic chemistry,
heterocycles, piperidines, expansion
Introduction
Since the classical textbook example of tropinone syn-
thesis, alicyclic and open-chain dialdehydes have been re-
garded as valuable scaffolds. They allow the construction of
various saturated N-heterocyclic systems with different
substituents and can serve as precursors that enable access
to highly functionalized β-amino acid derivatives. Thus, the
oxidative ring cleavage of unsaturated carbocyclic com-
pounds followed by ring closure under reductive amination
conditions serves as a methodology for the preparation of
some heterocyclic systems (Figure 1), such as highly substi-
tuted piperidines, morpholine derivatives, and N-bridged
bicyclic scaffolds.1
The oxidative ring cleavage of unsaturated, substituted
mono- or bicyclic compounds, followed by transformations
of the resulting diformyl intermediates as useful substrates,
is an efficient and convenient tool for the synthesis of func-
tionalized acyclic or monocyclic derivatives.2
Given the high chemical and biological relevance of β-
amino acids,3 during the last decade we have focused devel-
oping ways to access this type of compound. Based on these
studies, our group has demonstrated that various carbocy-
clic and acyclic dialdehydes, derived from unsaturated
mono- or bicyclic substances are useful intermediates for
the synthesis of various functionalized β-amino derivatives.
A stereocontrolled transformation of unsaturated β-
amino acids involving diformyl cyclopentanes is illustrated
in Scheme 1. Carbocyclic dialdehydes, derived from nor-
bornene β-amino acid stereoisomers by oxidative cleavage,
were converted under Wittig reaction conditions into the
corresponding alkenylated cyclopentane β-amino acid de-
rivatives (Scheme 1).4
Scheme 1  Stereocontrolled synthesis of functionalized alkenylated cy-
clopentanes from disubstituted norbornenes via diformyl intermediates
Figure 1  General scheme for the transformation of cycloalkenes into 
N-heterocycles via dialdehydes
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above was efficiently extended to the synthesis of various
functionalized open-chain β-amino acid derivatives. Start-
ing from cis- or trans-cyclopentene β-amino acids, dialde-
hyde intermediates furnished the corresponding anti- and
syn-dialkenylated acyclic derivatives with conservation of
the configuration of the chiral centers (Scheme 2).5
By applying a similar strategy, the six-membered amino
acid stereoisomers, after oxidative ring opening and Wittig
olefination, provided novel functionalized open-chain β-
amino acid derivatives.6Biographical SketchesD
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l.Fluorinated organic molecules,7 including fluorine-con-
taining amino acid derivatives,8 have generated increasing
attention among medicinal chemists and such compounds
have had a high impact on drug research over the last de-
cade.8 Our research group has applied various selective ste-
reocontrolled strategies to gain access to a range of fluori-
nated β-amino acid derivatives.8c An approach to fluorinat-
ed scaffolds consisted of the transformation of diformyl
cyclopentane β-amino esters derived from norbornene β-
amino acid stereoisomers (Scheme 3).9
Scheme 3  Chemoselective synthesis of highly functionalized fluorinat-
ed scaffolds from disubstituted norbornenes via diformyl intermediates
Dialdehyde scaffolds resulting from oxidative ring cleav-
age of unsaturated bicyclic β-lactams were used as excel-
lent precursors for the synthesis of N-heterocyclic β-amino
esters (Scheme 4). Double reductive amination of diformyl
β-amino esters with benzylamine or fluorinated amines af-
forded stereoisomers of piperidine or azepane β-amino es-
ters.8d,10a,b Starting from di-exo- or di-endo-norbornene β-
amino acids, the ring expansion with reductive amination
resulted in the formation of N-bridged bicyclic β-amino es-
ters.8d,10c
The reductive amination protocol was efficiently ex-
tended further to enable access to tashiromine and epi-
tashiromine natural alkaloids. Diformyl amino ester stereo-
isomers, accessed from cis- or trans-cyclooctene β-amino
esters, underwent intramolecular cyclization under reduc-
tive amination and led to the corresponding indolizidine al-
kaloids.11
Scheme 2  Stereocontrolled synthesis of highly functionalized acyclic 
dienes from disubstituted cyclopentene stereoisomers via diformyl in-
termediates
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Scheme 4  Stereocontrolled synthesis of piperidine and azepane β-
amino acid derivatives from unsaturated bicyclic β-lactams via diformyl 
intermediates
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nal products prepared by using the above methodologies,
based on the cyclization by reductive amination, were pre-
determined by the configurations of the stereocenters of
the starting materials (Scheme 5).
Results and Discussion
Our current aim is to offer an insight into the extension
by generalization of the synthetic method summarized
above. The protocol involves oxidative ring opening of vari-
ous cycloalkenes followed by cyclization of the diformyl de-
rivatives under reductive amination conditions, to synthe-
size various N-heterocyclic scaffolds that incorporate fluo-
rinated entities in their structure. Taking into consideration
the high biorelevance of N-heterocycles and organofluorine
scaffolds, we decided to investigate the formation of fluo-
rine-containing N-heterocyclic systems from various sub-
stituted dialdehydes. The latter compounds were derived
from selected mono- or disubstituted cycloalkenes.
First, we explored the behavior of substituted five-
membered cycloalkenes; namely, a cyclopentene carboxyl-
ate and a cyclopenteneamine. Cyclopentene benzyl ester 2
(prepared from the commercially available cyclopent-3-en-
ecarboxylic acid 1) was submitted to dialdehyde formation
(Scheme 6). First, 2 was oxidized with N-methylmorpholine
N-oxide (NMO)/OsO4 to generate the corresponding vicinal
diol derivatives 3 as a mixture of stereoisomers in nearly
1:1 ratio, which could not be separated either by crystalli-
zation or by chromatography. Given that the stereocenters
are removed in the next oxidative ring cleavage step, the di-
astereoisomeric diol mixture 3 was used further without
separation. Oxidation with NaIO4 provided the correspond-
ing unstable acyclic dialdehyde 4, which was submitted
without isolation or purification to a reductive ring-closure
step. The latter reaction was initially performed with the
commercially available fluorine-containing amine, 2,2,2-
trifluoroethylamine. Diformyl intermediate 4, upon reac-
tion with the fluorine-containing amine noted above, fol-
lowed by treatment with NaBH3CN, furnished the corre-
sponding trifluoromethylated piperidine derivative 5.
The ring-closing protocol based on reductive amination
of dialdehydes could be applied by using other fluorine-
containing building blocks, which allowed access to other
fluorinated piperidines. Illustrative is the treatment of di-
formyl derivative 4 with the commercially available 2,2-di-
fluoromethylamine or 2-fluoroethylamine followed by re-
duction, affording the corresponding mono- or difluorinat-
ed piperidine derivatives 6 and 7 (Scheme 6).
Next, the substituent on the cyclopentene ring was
changed from an ester to a protected amine. Commercially
accessible unsaturated acid 1 was converted under Curtius
reaction conditions into Cbz-protected amine 8, the dihy-
droxylation of which furnished a 1:1 mixture of diol deriva-
tive 9 (Scheme 7). Again, this mixture was used in the next
step without separation of the components, giving dialde-
hyde 10. Without isolation, this unstable dialdehyde was
transformed in the reaction with 2,2,2-trifluoroethylamine
in the presence of NaBH3CN into trifluoromethylated piper-
idine 11 in good yield.
Scheme 7  Synthesis of functionalized piperidine derivative 11 from 
cyclopentene carboxylate via a diformyl intermediate
The transformation of dialdehyde substrates could be
applied not only for the synthesis of piperidines but also for
the construction of seven-membered functionalized N-het-
erocyclic systems. For this synthesis, we selected the six-
membered analogues of the cyclopentene ester and amine
studied above. Thus, commercially available ethyl cyclohex-
3-enecarboxylate (12) was first subjected to dihydroxyl-
Scheme 6  Synthesis of functionalized piperidine derivatives 5–7 from 
cyclopentene carboxylate via a diformyl intermediate
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l.ation, yielding 13 as a mixture of diol diastereoisomers
(1:1) (Scheme 8). Analogous to the five-membered counter-
part, these could not be separated and, therefore, were used
directly for ring opening with NaIO4 affording the corre-
sponding open-chain dialdehyde 14. Unstable diformyl in-
termediate 14 was next converted without isolation on
treatment with trifluorinated ethylamine into azepane de-
rivative 15.
Scheme 8  Synthesis of functionalized azepane derivative 15 from cy-
clohexene carboxylate via a diformyl intermediate
The synthesis of a fluorinated azepane bearing a Cbz-
protected amine substituent could be achieved by starting
from the commercially accessible cyclohex-3-enecarboxylic
acid (16; Scheme 9). Cyclohexeneamine 17, synthesized by
Curtius reaction from 16, led by dihydroxylation to diol
mixture 18, which was subjected to oxidative ring cleavage
in the presence of NaIO4.
Scheme 9  Synthesis of functionalized azepane derivative 20 from eth-
yl cyclohexene carboxylate via a diformyl intermediate
The formed unstable dialdehyde derivative 19 was fur-
ther used without isolation. On treatment with 2,2,2-tri-
fluroethylamine hydrochloride in EtOH, in the presence of
NaHCO3 and NaBH3CN, ring closure involving reductive am-
ination took place, resulting in the corresponding substitut-
ed azepane derivatives 20 containing a trifluoromethyl
group (Scheme 9). Notably, formation of the seven-mem-
bered ring system proceeded with lower yield in compari-
son to those of the six-membered analogues.
As a continuation of the study, our next aim was to syn-
thesize disubstituted trifluoromethylated N-heterocyclic
derivatives. Dihydroxylation of the olefin bond of the com-
mercially available cyclohexene cis-diester 21 afforded vici-
nal diol 22 (Scheme 10). Subsequent oxidative ring opening
of 22 mediated by NaIO4 followed by reductive ring closure
with trifluoroethylamine afforded, via dialdehyde 23, aze-
pane diester 24. Again, given that the stereocenters are not
affected during the ring expansion procedure, the configu-
rations of the chiral centers in 24 are predetermined by the
structure of the starting material 21.
Scheme 10  Synthesis of functionalized azepane derivative 24 from cy-
clohexene dicarboxylate via a diformyl intermediate
In view of the high physiological relevance of N-bridged
bicyclic derivatives (e.g., cocaine, anatoxin-a analogues),3a,e
our next aim was to extend the synthetic technique de-
scribed above to the preparation of trifluoromethylated N-
bicyclic systems. Thus, di-endo-norbornene dicarboxylate
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Scheme 11  Synthesis of functionalized bicyclic derivative 28 from nor-
bornene dicarboxylate via a diformyl intermediate
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l.2515 was transformed by dihydroxylation into diol deriva-
tive 26, then the oxidative ring opening followed by reduc-
tive amination with trifluoroethylamine and NaBH3CN,
provided N-bicyclic diester 28 via diformyl derivative 27
(Scheme 11).
Conclusions
We have demonstrated the high value of substituted
open-chain or alicyclic dialdehyde derivatives for the syn-
thesis by double reductive amination of different types of
N-heterocycles. In the current study we investigated the ap-
plication of this synthetic procedure for the construction of
functionalized fluorine-containing N-heterocyclic systems.
The method includes the reaction of functionalized di-
formyl scaffolds, accessed by oxidative ring opening of vari-
ous substituted cycloalkenes, with simple, commercially
available fluorinated amines. Taking into consideration the
availability of both a wide variety of cycloalkenes and func-
tionalized primary amine building blocks, this convenient
methodology might be further applied towards the synthe-
sis of a series of functionalized saturated N-heterocycles.
The chemicals were purchased from Sigma-Aldrich and were used
without further purification. The NMR spectra were recorded at 400
MHz with CDCl3 or DMSO-d6 as the solvent and tetramethylsilane as
the internal standard. The solvents were used as received from the
suppliers. Melting points were determined with a Kofler apparatus.
Elemental analyses were recorded on a Perkin-Elmer CHNS-2400 Ser
II elemental analyser. Silica gel 60 F254 was purchased from Merck.
Synthesis of N-Protected Cycloalkeneamines; General Procedure
To a solution of cycloalkencarboxylic acid (12 mmol) in anhydrous
toluene (30 mL), Et3N (12 mmol) and diphenylphosphoryl azide
(DPPA, 12 mmol) were added and the resulting mixture was stirred
for 2 h at r.t. and then for 1 h at 90 °C. A solution of benzyl alcohol
(13.8 mmol) was added to this solution and the mixture was stirred
overnight at 90 °C. The mixture was then diluted with EtOAc (40 mL)
and washed with NaHCO3 (2 × 20 mL). The organic layer was dried
over Na2SO4 and concentrated under vacuo. The crude material was
purified by column chromatography on silica gel (n-hexane/EtOAc).
Esterification of Cycloalkenecarboxylic Acids; General Procedure
To a solution of cycloalkencarboxylic acid (9 mmol) in THF (50 mL),
benzyl chloride (9 mmol) and DBU (22.5 mmol) were added and the
solution was stirred for 3 h at 90 °C. Upon completion of the reaction,
the mixture was diluted with EtOAc (40 mL) and washed with H2O
(3 × 30 mL). The organic layer was dried (Na2SO4) and concentrated
under reduced pressure. The crude product was purified by column
chromatography on silica gel (n-hexane/EtOAc).
Dihydroxylation of Substituted Cycloalkenes; General Procedure
To a stirred solution of substituted cycloalkene (10 mmol), OsO4 (2%
in t-BuOH, 0.3 mL), and NMO (1.2 equiv) were added in acetone (30
mL) and the resulting mixture was stirred at r.t. for 3 h. Upon comple-
tion of the reaction, the mixture was treated with saturated aqueous
Na2SO3 solution and then extracted with CH2Cl2 (3 × 30 mL). The com-
bined organic layers were dried over Na2SO4, filtered, and evaporated
under reduced pressure. The crude product was purified by column
chromatography on silica gel (n-hexane/EtOAc).
Fluorine-Containing N-Heterocyclic Derivatives by Ring Closure 
with Reductive Amination; General Procedure
To a stirred solution of diol (2 mmol), NaIO4 (1.5 equiv) was added in
THF/H2O (25 mL/2 mL). After stirring the mixture for 1 h at 20 °C un-
der an Ar atmosphere, H2O was added until the precipitate dissolved
(ca. 40 mL). The mixture was then extracted with CH2Cl2 (3 × 20 mL),
the combined extract was dried over Na2SO4 and the resulting dialde-
hyde solution was evaporated. The crude product was used for the
next reaction without purification. Fluorine-containing ethylamine
hydrochloride (2 mmol), and NaHCO3 (2 equiv) were added to the
solution of the dialdehyde in EtOH (20 mL) and the mixture was
stirred at 20 °C for 10 min. NaBH3CN (2 mmol) and AcOH (2 drops)
were then added and stirring was continued for another 4 h at 20 °C.
The reaction mixture was diluted with H2O (20 mL), extracted with
CH2Cl2 (3 × 25 mL), and the combined organic layers were dried over
Na2SO4 and concentrated under reduced pressure. The residue was
purified by column chromatography on silica gel (n-hexane/EtOAc).
Benzyl Cyclopent-3-enecarboxylate (2)12
Yield: 64% (1.15 g); yellow oil; Rf = 0.26 (n-hexane/EtOAc, 20:1).
1H NMR (400 MHz, DMSO-d6): δ = 2.54–2.68 (m, 4 H, H-2, H-5), 3.15–
3.26 (m, 1 H, H-1), 5.12 (s, 2 H, OCH2), 5.68 (s, 2 H, CH=CH), 7.31–7.42
(m, 5 H, Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 36.8, 41.5, 66.5, 128.7, 128.9,
129.3, 129.8, 137.2, 179.3.
Anal. Calcd for C13H14O2: C, 77.20; H, 6.98. Found: C, 77.18; H, 6.97.
Benzyl Cyclopent-3-en-1-ylcarbamate (8)13
Yield: 65% (2.51 g); white solid; mp 31–32 °C; Rf = 0.33  (n-hex-
ane/EtOAc 8:1).
1H NMR (400 MHz, DMSO-d6): δ = 2.32–2.45 (m, 2 H, H-2, H-5), 2.73–
2.86 (m, 2 H, H-2, H-5), 4.27–4.39 (m, 1 H, H-1), 5.22 (s, 2 H, OCH2),
5.87 (s, 2 H, CH=CH), 7.47–7.70 (m, 6 H, Ar-H and N-H).
13C NMR (100 MHz, DMSO-d6): δ = 40.0, 51.1, 66.0, 120.8, 128.6,
129.2, 129.7, 138.1, 156.6.
Anal. Calcd for C13H14O2: C, 71.87; H, 6.96; N, 6.45. Found: C, 71.85; H,
6.95; N, 6.44.
Benzyl Cyclohex-3-en-1-ylcarbamate (17)14
Yield: 74% (508 mg); yellow solid; mp 47–49 °C; Rf = 0.30 (n-hex-
ane/EtOAc, 8:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.37–1.49 (m, 1 H, H-6), 1.76–1.84
(m, 1 H, H-5), 1.86–1.96 (m, 1 H, H-6), 2.04–2.11 (m, 2 H, H-2), 2.16–
2.26 (m, 1 H, H-5), 3.47–3.58 (m, 1 H, H-1), 5.02 (s, 2 H, OCH2), 5.54–
5.66 (m, 2 H, CH=CH), 7.18–7.26 (br s, 1 H, N-H), 7.29–7.43 (m, 5 H,
Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 25.4, 29.5, 32.3, 47.6, 66.4, 125.8,
127.4, 128.6, 129.2, 135.3, 155.5.
Anal. Calcd for C14H17NO2: C, 72.70; H, 7.41; N, 6.06. Found: C, 72.68;
H, 7.39; N, 6.05.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 1206–1213
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l.Dimethyl (1R*,2S*,3R*,4S*)-Bicyclo[2.2.1]hept-5-ene-2,3-dicarbox-
ylate (25)15
Yield: 89% (5.70 g); colorless oil; Rf = 0.42 (n-hexane/EtOAc, 4:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.23 (d, J = 8.8 Hz, 1 H, H-7), 1.37
(d, J = 8.8 Hz, 1 H, H-7), 3.05 (s, 2 H, H-2, H-3), 3.47 (s, 6 H, COOCH3),
3.51 (s, 2 H, H-1, H-4), 6.12 (s, 2 H, CH=CH).
13C NMR (100 MHz, DMSO-d6): δ = 46.6, 48.2, 48.9, 51.9, 135.6, 173.1.
Anal. Calcd for C11H14O4: C, 62.85; H, 6.71. Found: C, 62.83; H, 6.70.
Dimethyl (1R*,2S*,4S*,5R*)-4,5-Dihydroxycyclohexane-1,2-dicar-
boxylate (22)
Yield: 82% (1.93 g); yellow oil; Rf = 0.38 (n-hexane/EtOAc 1:3).
1H NMR (400 MHz, DMSO-d6): δ = 1.79–1.88 (m, 2 H, H-3, H-6), 1.89–
1.97 (m, 2 H, H-3, H-6), 2.99 (s, 2 H, OH), 3.52–3.63 (m, 8 H, COOCH3,
H-1, H-2), 4.45 (d, J = 4.4 Hz, 2 H, H-4, H-5).
13C NMR (100 MHz, DMSO-d6): δ = 30.7, 39.4, 52.3, 68.2, 174.5.
Anal. Calcd for C10H16O6: C, 51.72; H, 6.94. Found: C, 51.70; H, 6.93.
Dimethyl (1R*,2R*,3S*,4S*,5S*,6R*)-5,6-Dihydroxybicyc-
lo[2.2.1]heptane-2,3-dicarboxylate (26)16
Yield: 92% (1.07 g); colorless oil; Rf = 0.40 (n-hexane/EtOAc 1:4).
1H NMR (400 MHz, DMSO-d6): δ = 1.18 (d, J = 10.0 Hz, 1 H, H-7), 1.83
(d, J = 10.0 Hz, 1 H, H-7), 2.23 (s, 2 H, OH), 3.05 (t, J = 2.14 Hz, 2 H, H-1,
H-4), 3.54 (s, 6 H, COOCH3), 3.88–3.92 (m, 2 H, H-2, H-3), 4.57–4.63
(m, 2 H, H-5, H-6).
13C NMR (100 MHz, DMSO-d6): δ = 33.3, 44.6, 47.2, 52.0, 69.6, 172.8.
Anal. Calcd for C11H16O6: C, 54.09; H, 6.60. Found: C, 54.07; H, 6.59.
Benzyl [1-(2,2,2-Trifluoroethyl)azepan-4-yl]carbamate (20)
Yield: 20% (151 mg); yellow oil; Rf = 0.25 (n-hexane/EtOAc, 3:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.41–1.96 (m, 6 H, H-3, H-5, H-6),
2.68–2.89 (m, 4 H, 2-H, 7-H), 3.17–3.29 (m, 2 H, CH2-CF3), 3.48–3.60
(m, 1 H, H-4), 4.99 (s, 2 H, OCH2), 7.16–7.23 (br s, 1 H, N-H), 7.27–7.39
(m, 5 H, Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 25.2, 34.1, 35.6, 51.7, 52.0, 56.1,
57.5 and 57.8 and 58.1 and 58.3 (q, 2JC–F = 29.05, CCF3), 65.9, 125.9 (q,
1JC–F = 260.0 Hz, CF3), 128.3, 128.6, 129.2, 138.2, 156.0.
19F NMR (100 MHz, DMSO-d6): δ = –69.4.
MS (ESI): m/z = 331.3 [M + 1].
Anal. Calcd for C16H21F3N2O2: C, 58.17; H, 6.41; N, 8.48. Found: C,
58.15; H, 6.40; F, 17.23; N, 8.45.
Ethyl 1-(2,2,2-Trifluoroethyl)azepane-4-carboxylate (15)
Yield: 25% (2.045 g); colorless oil; Rf = 0.30 (n-hexane/EtOAc, 10:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.17 (t, J = 7.06 Hz, 3 H, CH3), 1.47–
1.77 (m, 4 H, H-5, H-6), 1.80–1.92 (m, 2 H, H-3), 2.51–2.57 (m, 1 H, H-
4), 2.72–2.93 (m, 4 H, H-2, H-7), 3.24–3.28 (m, 2 H, CF3CH2), 4.00–
4.09 (m, 2 H, CH2CH3).
13C NMR (100 MHz, DMSO-d6): δ = 15.0, 27.2, 30.1, 31.6, 43.8, 53.7,
55.9, 57.0 and 57.3 and 57.6 and 57.9 (q, 2JC–F = 29.2, CCF3), 60.6, 128.6
(q, 1JC–F = 280 Hz, CF3), 176.6.
19F NMR (100 MHz, DMSO-d6): δ = –69.5.
MS (ESI): m/z = 254.2 [M + 1].
Anal. Calcd for C11H18F3NO2: C, 52.17; H, 7.16; N, 5.53. Found: C,
52.14; H, 7.15; F, 22.48; N, 5.52.
Benzyl [1-(2,2,2-Trifluoroethyl)piperidin-4-yl]carbamate (11)
Yield: 64% (482 mg); white solid; mp 63–66 °C; Rf = 0.18 (n-hex-
ane/EtOAc, 4:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.35–1.48 (m, 2 H, H-3, H-5,), 1.71
(d, J = 13.2 Hz, 2 H, H-3, H-5), 2.36 (t, J = 11.6 Hz, 2 H, H-2, H-6), 2.86
(d, J = 12.4 Hz, 2 H, H-2, H-6), 3.06–3.18 (m, 2 H, CH2CF3), 5.00 (s, 2 H,
OCH2), 7.21 (br s, 1 H, N-H), 7.27–7.40 (m, 5 H, Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 32.5, 48.2, 53.3, 57.3 and 57.5 and
57.8 and 58.1 (q, 2JC–F = 28.0 Hz, CCF3), 66.0, 128.3 (q, 1JC–F = 260 Hz,
CF3), 128.6, 129.2, 138.2, 156.2.
19F NMR (100 MHz, DMSO-d6): δ = –68.1.
MS (ESI): m/z = 317.3 [M + 1].
Anal. Calcd for C15H19F3N2O2: C, 56.96; H, 6.05; N, 8.86; found: C,
56.93; H, 6.04; F, 18.00; N, 8.84.
Benzyl 1-(2,2,2-Trifluoroethyl)piperidine-4-carboxylate (5)
Yield: 67% (514 mg); brown oil; Rf = 0.33 (n-hexane/EtOAc, 10:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.53–1.65 (m, 2 H, H-3, H-5), 1.77–
1.85 (m, 2 H, H-3, H-5 ), 2.34–2.43 (m, 3 H, H-2, H-4, H-6), 2.82–2.90
(m, 2 H, H-2, H-6), 3.08–3.18 (m, 2 H, CH2CF3), 5.10 (s, 2 H, OCH2),
7.29–7.40 (m, 5 H, Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 28.8, 40.5, 53.4, 57.4 and 57.7 and
58.0 and 58.3 (q, 2JC–F = 29.0 Hz, CCF3), 66.3, 125.5 (q, 1JC–F = 275.6 Hz,
CF3), 128.6, 128.8, 129.3, 137.2, 174.9.
19F NMR (100 MHz, DMSO-d6): δ = –69.1.
MS (ESI): m/z = 302.3 [M + 1].
Anal. Calcd for C15H18F3NO2: C, 59.79; H, 6.02; N, 4.65. Found: C,
59.75; H, 6.00; F, 18.90; N, 4.64.
Dimethyl (4R*,5S*)-1-(2,2,2-Trifluoroethyl)azepane-4,5-dicarbox-
ylate (24)
Yield: 39% (303 mg); colorless oil; Rf = 0.12 (n-hexane/EtOAc, 10:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.84–1.95 (m, 2 H, H-3, H-6), 1.95–
2.09 (m, 2 H, H-3, H-6), 2.71–2.86 (m, 4 H, H-2, H-7), 2.98–3.07 (m,
2 H, H-4, H-5), 3.17–3.28 (m, 2 H, CH2CF3), 3.57 (s, 6 H, COOCH3).
13C NMR (100 MHz, DMSO-d6): δ = 28.8, 44.5, 52.2, 53.3, 57.6 and 57.9
and 58.2 and 58.5 (q, 2JC–F = 29.2 Hz, CCF3), 125.6, 128.4 (q, 1JC–F =
279.6 Hz, CF3), 174.1.
19F NMR (100 MHz, DMSO-d6): δ = –69.7.
MS (ESI): m/z = 298.2 [M + 1].
Anal. Calcd for C12H18F3NO4: C, 48.48; H, 6.10; F, 19.17; N, 4.71. Found:
C, 48.45; H, 6.09; F, 19.15; N, 4.70.
Dimethyl (1R*,5S*,6R*,7R*)-3-(2,2,2-Trifluoroethyl)-3-azabicyc-
lo[3.2.1]octane-6,7-dicarboxylate (28)
Yield: 29% (254 mg); white solid; mp 52–55 °C; Rf = 0.35 (n-hex-
ane/EtOAc, 8:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.48 (d, J = 12 Hz, 1 H, H-8), 1.60–
1.68 (m, 1 H, H-8), 2.29 (s, 2 H, H-5, H-5), 2.54 (s, 2 H, H-2, H-4), 2.95–
3.05 (m, 2 H, CH2CF3), 3.13–3.18 (m, 2 H, H-2, H-4), 3.23–3.27 (m, 2 H,
6-H, 7-H), 3.54 (s, 6 H, COOCH3).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 1206–1213
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l.13C NMR (100 MHz, DMSO-d6): δ = 37.8, 38.2, 46.0, 51.6, 55.5, 57.1
and 57.4 and 57.7 and 58.0 (q, 2JC–F = 29.0 Hz, CCF3), 128.3 (q, 1JC–F =
270 Hz, CF3), 172.2.
19F NMR (100 MHz, DMSO-d6): δ = –66.9.
MS (ESI): m/z = 310.3 [M + 1].
Anal. Calcd for C13H18F3NO4: C, 50.48; H, 5.87; F, 18.43; N, 4.53. Found:
C, 50.45; H, 5.86; F, 18.40; N, 4.52.
Benzyl 1-(2,2-Difluoroethyl)piperidine-4-carboxylate (6)
Yield: 79% (566 mg); colorless oil; Rf = 0.18 (n-hexane/EtOAc, 8:1).
1H NMR (400 MHz, DMSO-d6): δ = 1.41–1.57 (m, 2 H, H-3, H-5), 1.64–
1.78 (m, 2 H, H-3, H-5), 2.05–2.16 (m, 2 H, H-2, H-6), 2.18–2.32 (m,
1 H, H-4), 2.49–2.64 (td, J = 15.7, 4.28 Hz, 2 H, CH2CHF), 2.66–2.78 (m,
2 H, H-2, H-6), 4.99 (s, 2 H, OCH2), 5.78–6.16 (tt, J = 55.7, 4.35 Hz, 1 H,
CHF2), 7.16–7.35 (m, 5 H, Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 28.8, 40.7, 53.7, 60.0 and 60.2 and
60.5 (t, 2JC–F = 24.1 Hz, CCHF2), 66.2, 114.40 and 116.8 and 119.2 (t, 1JC–F =
237.6 Hz, CHF2), 128.6, 128.8, 129.3, 137.2, 174.9.
19F NMR (100 MHz, DMSO-d6): δ = –115.1.
MS (ESI): m/z = 284.33 [M + 1].
Anal. Calcd for C15H19F2NO2: C, 63.59; H, 6.76; F, 13.41; N, 4.94. Found:
C, 63.56; H, 6.75; F, 13.39; N, 4.93.
Benzyl 1-(2-Fluoroethyl)piperidine-4-carboxylate (7)
Yield: 55% (290 mg); colorless oil; Rf = 0.25 (n-hexane/EtOAc, 1:4).
1H NMR (400 MHz, DMSO-d6): δ = 1.52–1.68 (m, 2 H, H-3, H-5), 1.76–
1.89 (m, 2 H, H-3, H-5), 2.01–2.14 (m, 2 H, H-2, H-6), 2.30–2.41 (m,
1 H, H-4), 2.52–2.66 (dt, J = 28.3, 4.9 Hz, 2 H, CH2CH2F), 2.77–2.86 (m,
2 H, H-2, H-6), 4.41–4.60 (dt, J = 47.8, 4.9 Hz, 2 H, CH2F), 5.01 (s, 2 H,
OCH2), 7.29–7.41 (m, 5 H, Ar-H).
13C NMR (100 MHz, DMSO-d6): δ = 28.8, 41.0, 53.4, 58.5 and 58.7 (d,
2JC–F = 20.0 Hz, CCH2F), 66.2, 81.9 and 83.6 (d, 1JC–F = 163.5 Hz, CH2F),
128.6, 128.8, 129.3, 137.2, 175.0.
19F NMR (100 MHz, DMSO-d6): δ = –216.8.
MS (ESI): m/z = 266.32 [M + 1].
Anal. Calcd for C15H20FNO2: C, 67.90; H, 7.60; F, 7.16; N, 5.28. Found:
C, 67.88; H, 7.59; F, 7.15; N, 5.27.
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